CD40 and cancer: Current research is now focused on strategies to overcome stromal barriers and to “reprogram” or deplete immunosuppressive cell populations within the TME, such as using CD40 agonists, CSF-1R inhibitors, or therapies targeting cancer-associated fibroblasts.